Biotron's BIT225 Shows Strong Hep C Antiviral Activity

Share

Follow Us

Print this page

Biotron study of lead Hepatitis C drug shows virus undetectable in patients after three months

Wednesday, December 07, 2011 by Angela Kean

Biotron (ASX: BIT) has revealed positive results from a phase 2a trial of its lead Hepatitis C drug candidate, BIT225, that show 87% of patients receiving the drug had an undetectable virus after three months of treatment.

BIT225 targets the viral protein p7, which plays a crucial role in virus replication and reproduction. It is a new target, and BIT225 is a first-in-class direct acting antiviral.
The 28 day study treated patients with a combination of BIT225 and current approved standard of care therapies interferon alfa-2b plus ribavirin.

Continue reading this entire article:
http://www.proactiveinvestors.com.au/companies/news/23174/biotron-study-of-lead-hepatitis-c-drug-shows-virus-undetectable-in-patients-after-three-months–23174.html

Download Our Free Reports

Inside you'll discover:

• Things You May Not Know About Hepatitis C
• 7 Liver Detox SUPER Foods Your Doctor Isn't Telling You About
• 5 Dangerous Foods That Will Wreak Havoc On Your Liver
• A free "Mystery" Gift Valued at $9.99

Email address

Download Now

You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.